Per Ryberg
Papers
1
Total Citations
31
H-Index
1
About
Per Ryberg is a leading figure in asymmetric catalysis and sustainable synthetic methodology, with a particular focus on the development of efficient, enantioselective transformations for pharmaceutical intermediates. His work masterfully bridges the gap between fundamental organometallic chemistry and practical drug synthesis. A standout contribution is his high-throughput screening of a 21-member catalyst library for the asymmetric transfer hydrogenation of heteroaromatic ketones. This landmark study, which has garnered 31 citations, not only identified highly selective ruthenium and rhodium catalysts but also enabled the concise formal syntheses of two blockbuster antidepressants, (R)-Fluoxetine (Prozac) and (S)-Duloxetine (Cymbalta). By systematically exploring hydroxy amide, thioamide, and hydroxamic acid ligands, Ryberg demonstrated how rational catalyst design can solve complex stereochemical challenges in medicinal chemistry. His research is characterized by a pragmatic, application-driven approach that accelerates the discovery of chiral building blocks. For students and researchers, Ryberg’s work exemplifies how high-throughput experimentation and mechanistic insight can converge to create impactful, industrially relevant catalytic processes.
Research Focus
Key Achievements
Top Papers
- 1